33 results on '"Ebot, Ericka M."'
Search Results
2. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2–ERG fusions
- Author
-
Chalmers, Zachary R., Burns, Michael C., Ebot, Ericka M., Frampton, Garrett M., Ross, Jeffrey S., Hussain, Maha H. A., and Abdulkadir, Sarki A.
- Published
- 2021
- Full Text
- View/download PDF
3. Transcriptional landscape of PTEN loss in primary prostate cancer
- Author
-
Imada, Eddie Luidy, Sanchez, Diego Fernando, Dinalankara, Wikum, Vidotto, Thiago, Ebot, Ericka M., Tyekucheva, Svitlana, Franco, Gloria Regina, Mucci, Lorelei Ann, Loda, Massimo, Schaeffer, Edward Matthew, Lotan, Tamara, and Marchionni, Luigi
- Published
- 2021
- Full Text
- View/download PDF
4. The association of diabetes with risk of prostate cancer defined by clinical and molecular features
- Author
-
Feng, Xiaoshuang, Song, Mingyang, Preston, Mark A., Ma, Wenjie, Hu, Yang, Pernar, Claire H., Stopsack, Konrad H., Ebot, Ericka M., Fu, Benjamin C., Zhang, Yiwen, Li, Ni, Dai, Min, Liu, Lydia, Giovannucci, Edward L., and Mucci, Lorelei A.
- Published
- 2020
- Full Text
- View/download PDF
5. SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis.
- Author
-
Rajanala, Sai Harisha, Plym, Anna, Vaselkiv, Jane B, Ebot, Ericka M, Matsoukas, Konstantina, Lin, Zhike, Chakraborty, Goutam, Markt, Sarah C, Penney, Kathryn L, Lee, Gwo-Shu M, Mucci, Lorelei A, Kantoff, Philip W, and Stopsack, Konrad H
- Abstract
Solute carrier organic anion (SLCO) transporters (OATP transporters) are involved in cellular uptake of drugs and hormones. Germline variants in SLCO1B3 and SLCO2B1 have been implicated in prostate cancer progression and therapy response, including to androgen deprivation and statin medications, but results have appeared heterogeneous. We conducted a cohort study of five single-nucleotide polymorphisms (SNPs) in SLCO1B3 and SLCO2B1 with prior evidence among 3208 men with prostate cancer who participated in the Health Professionals Follow-up Study or the Physicians' Health Study, following participants prospectively after diagnosis over 32 years (median, 14 years) for development of metastases and cancer-specific death (lethal disease, 382 events). Results were suggestive of, but not conclusive for, associations between some SNPs and lethal disease and differences by androgen deprivation and statin use. All candidate SNPs were associated with SLCO mRNA expression in tumor-adjacent prostate tissue. We also conducted a systematic review and harmonized estimates for a dose-response meta-analysis of all available data, including 9 further studies, for a total of 5598 patients and 1473 clinical events. The A allele of the exonic SNP rs12422149 (14% prevalence), which leads to lower cellular testosterone precursor uptake via SLCO2B1, was associated with lower rates of prostate cancer progression (hazard ratio per A allele, 0.80; 95% confidence interval, 0.69–0.93), with little heterogeneity between studies (I
2 , 0.27). Collectively, the totality of evidence suggests a strong association between inherited genetic variation in SLCO2B1 and prostate cancer prognosis, with potential clinical use in risk stratification related to androgen deprivation therapy. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
6. Regular aspirin use and gene expression profiles in prostate cancer patients
- Author
-
Stopsack, Konrad H., Ebot, Ericka M., Downer, Mary K., Gerke, Travis A., Rider, Jennifer R., Kantoff, Philip W., and Mucci, Lorelei A.
- Published
- 2018
7. Single-nucleotide polymorphisms in DNMT3B gene and DNMT3B mRNA expression in association with prostate cancer mortality
- Author
-
Zelic, Renata, Fiano, Valentina, Ebot, Ericka M., Coseo Markt, Sarah, Grasso, Chiara, Trevisan, Morena, De Marco, Laura, Delsedime, Luisa, Zugna, Daniela, Mucci, Lorelei A., and Richiardi, Lorenzo
- Published
- 2019
- Full Text
- View/download PDF
8. Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer
- Author
-
Ebot, Ericka M., Gerke, Travis, Labbé, David P., Sinnott, Jennifer A., Zadra, Giorgia, Rider, Jennifer R., Tyekucheva, Svitlana, Wilson, Kathryn M., Kelly, Rachel S., Shui, Irene M., Loda, Massimo, Kantoff, Philip W., Finn, Stephen, Vander Heiden, Matthew G., Brown, Myles, Giovannucci, Edward L., and Mucci, Lorelei A.
- Published
- 2017
- Full Text
- View/download PDF
9. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer
- Author
-
Ahearn, Thomas U., Pettersson, Andreas, Ebot, Ericka M., Gerke, Travis, Graff, Rebecca E., Morais, Carlos L., Hicks, Jessica L., Wilson, Kathryn M., Rider, Jennifer R., Sesso, Howard D., Fiorentino, Michelangelo, Flavin, Richard, Finn, Stephen, Giovannucci, Edward L., Loda, Massimo, Stampfer, Meir J., De Marzo, Angelo M., Mucci, Lorelei A., and Lotan, Tamara L.
- Published
- 2016
- Full Text
- View/download PDF
10. Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer.
- Author
-
Pernar, Claire H., Parmigiani, Giovanni, Giovannucci, Edward L., Rimm, Eric B., Tyekucheva, Svitlana, Loda, Massimo, Finn, Stephen P., Heiden, Matthew G. Vander, Fiorentino, Michelangelo, Ebot, Ericka M., and Mucci, Lorelei A.
- Abstract
Background: Men engaged in high physical activity have lower risks of advanced and fatal prostate cancer. Mechanisms underlying this association are not well understood but may include systemic and tumor-specific effects. We investigated potential mechanisms linking physical activity and gene expression in prostate tissue from men with prostate cancer. Methods: We included a subset of 118 men in the Health Professionals Follow-up Study diagnosed with prostate cancer between 1986 and 2005 with whole-transcriptome gene expression profiling on tumor and adjacent normal prostate tissue and physical activity data. Long-term vigorous physical activity was self-reported as the average time spent engaged in various forms of recreational physical activity at baseline and biennially until prostate cancer diagnosis. Gene set enrichment analysis was performed among KEGG and Hallmark gene sets to identify pathways with differential expression based on vigorous physical activity. Results: In adjacent normal tissue, we identified 25 KEGG gene sets enriched (downregulated) in the highest compared with lowest quintile of vigorous physical activity at an FDR <0.10, including a number of cancer- and immune-related pathways. Although no gene sets reached statistical significance in tumor tissue, top gene sets differentially expressed included TGF beta, apoptosis, and p53 signaling pathways. Conclusions: These findings suggest that physical activity may influence the tumor microenvironment. Future studies are needed to confirm these findings and further investigate potential mechanisms linking physical activity to lethal prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer.
- Author
-
Stopsack, Konrad H, Gerke, Travis, Zareba, Piotr, Pettersson, Andreas, Chowdhury, Dipanjan, Ebot, Ericka M, Flavin, Richard, Finn, Stephen, Kantoff, Philip W, Stampfer, Meir J, Loda, Massimo, Fiorentino, Michelangelo, and Mucci, Lorelei A
- Subjects
MEDICAL personnel ,LETHAL mutations ,BRCA genes ,TUMOR proteins ,DNA repair ,CASTRATION-resistant prostate cancer ,PROSTATE cancer - Abstract
DNA repair genes are commonly altered in metastatic prostate cancer, but BRCA1 mutations are rare. Preliminary studies suggest that higher tumor expression of the BRCA1 protein may be associated with worse prognosis. We undertook a prospective study among men with prostate cancer in the Health Professionals Follow-up Study and evaluated BRCA1 via immunohistochemical staining on tissue microarrays. BRCA1 was expressed in 60 of 589 tumors. Prevalence of BRCA1 positivity was 43% in the 14 men with metastases at diagnosis compared with 9% in non-metastatic tumors [difference, 33 percentage points; 95% confidence interval (CI), 7–59]. BRCA1-positive tumors had 2.16-fold higher Ki-67 proliferative indices (95% CI, 1.18–3.95), higher tumor aneuploidy as predicted from whole-transcriptome profiling, and higher Gleason scores. Among the 575 patients with non-metastatic disease at diagnosis, we evaluated the association between BRCA1 expression and development of lethal disease (metastasis or cancer-specific death, 69 events) during long-term follow-up (median, 18.3 years). A potential weak association of BRCA1 positivity with lethal disease (hazard ratio, 1.61; 95% CI, 0.82–3.15) was attenuated when adjusting for age, Gleason score and clinical stage (hazard ratio, 1.11; 95% CI, 0.54–2.29). In summary, BRCA1 protein expression is a feature of more proliferative and more aneuploid prostate tumors and is more common in metastatic disease. While not well suited as a prognostic biomarker in primary prostate cancer, BRCA1 protein expression may be most relevant in advanced disease. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Family history of prostate cancer and the incidence of ERG‐ and phosphatase and tensin homolog‐defined prostate cancer.
- Author
-
Hashim, Dana, Gonzalez‐Feliciano, Amparo G., Ahearn, Thomas U., Pettersson, Andreas, Barber, Lauren, Pernar, Claire H., Ebot, Ericka M., Isikbay, Masis, Finn, Stephen P., Giovannucci, Edward L., Lis, Rosina T., Loda, Massimo, Parmigiani, Giovanni, Lotan, Tamara, Kantoff, Philip W., Mucci, Lorelei A., and Graff, Rebecca E.
- Subjects
FAMILY history (Medicine) ,PTEN protein ,MEDICAL personnel - Abstract
Family history is among the strongest known risk factors for prostate cancer (PCa). Emerging data suggest molecular subtypes of PCa, including two somatic genetic aberrations: fusions of androgen‐regulated promoters with ERG and, separately, phosphatase and tensin homolog (PTEN) loss. We examined associations between family history and incidence of these subtypes in 44,126 men from the prospective Health Professionals Follow‐up Study. ERG and PTEN status were assessed by immunohistochemistry. Multivariable competing risks models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for associations between self‐reported family history of PCa and molecular subtypes of disease. Thirteen percent of men had a positive family history of PCa at baseline. During a median follow‐up of 18.5 years, 5,511 PCa cases were diagnosed. Among them, 888 were assayed for ERG status (47% ERG‐positive) and 715 were assayed for PTEN loss (14% PTEN null). Family history was more strongly associated with risk of ERG‐negative (HR: 2.15; 95% CI: 1.71–2.70) than ERG‐positive (HR: 1.49; 95% CI: 1.13–1.95) disease (pheterogeneity: 0.04). The strongest difference was among men with an affected father (HRERG‐negative: 2.09; 95% CI: 1.64–2.66; HRERG‐positive: 1.30; 95% CI: 0.96–1.76; pheterogeneity: 0.01). Family history of PCa was positively associated with both PTEN null (HR: 2.10; 95% CI: 1.26–3.49) and PTEN intact (HR: 1.72; 95% CI: 1.39–2.13) PCa (pheterogeneity: 0.47). Our results indicate that PCa family history may be positively associated with PCa in all ERG and PTEN subtypes, suggesting a role of genetic susceptibility in their development. It is possible that ERG‐negative disease could be especially associated with positive family history. What's new? Family history is among the strongest known risk factors for prostate cancer (PCa). Despite progress in defining molecular subtypes of PCa, little is known about their heritability. Here, the authors examine associations between family history and incidence of PCa defined by fusions of androgen‐regulated promoters with ERG and, separately, PTEN loss in 44,126 men from the prospective Health Professionals Follow‐up Study. The results indicate that family history may be positively associated with PCa in all ERG and PTEN subtypes, suggesting a role for genetic susceptibility in their development. Furthermore, ERG‐negative disease could potentially be especially associated with positive family history. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer.
- Author
-
Yiwen Zhang, Ke Zhou, Cindy, Rencsok, Emily M., Fall, Katja, Lotan, Tamara L., Loda, Massimo, Giunchi, Francesca, Platz, Elizabeth A., De Marzo, Angelo M., Mucci, Lorelei A., Fiorentino, Michelangelo, and Ebot, Ericka M.
- Abstract
Background: Inflammation and focal atrophy are common features adjacent to prostate tumors. Limited evidence exists on whether these features have prognostic significance. Methods: In the Health Professionals Follow-Up Study and Physicians' Health Study, we studied 1,035 men diagnosed with prostate cancer. A genitourinary pathologist centrally reviewed tumor and normal areas of hematoxylin and eosin slides from prostate cancer specimens for the presence of acute and chronic inflammation, and four subtypes of focal atrophy. Cox proportional hazards models adjusted for potential confounders were used to estimate HRs and 95% confidence intervals (CI) for the association of these features with lethal prostate cancer, defined as development of metastatic disease or death during follow-up. Results: During a median of 12 years of follow-up, 153 men developed lethal prostate cancer. A total of 84% of men had histologic evidence of chronic inflammation and 30% had acute inflammation. Both chronic and acute inflammation were inversely associated with lethal prostate cancer in age- and lifestyle-adjusted models. Chronic inflammation remained inversely associated with lethal prostate cancer after additionally adjusting for prognostic clinical features (HR = 0.45; 95% CI, 0.30-0.69 for mild and HR = 0.51; 95% CI, 0.33-0.80 for moderate to severe). None of the atrophic lesions were associated with lethal prostate cancer. Conclusions: Our data suggest that the presence of inflammation, particularly chronic inflammation, in prostate cancer tissue is associated with better prognosis among patients with prostate cancer. Impact: This is the largest prospective cohort study to examine the association between inflammation, focal atrophy, and lethal prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
- Author
-
Pernar, Claire H., Ebot, Ericka M., Pettersson, Andreas, Graff, Rebecca E., Giunchi, Francesca, Ahearn, Thomas U., Gonzalez-Feliciano, Amparo G., Markt, Sarah C., Wilson, Kathryn M., Stopsack, Konrad H., Gazeeva, Elizaveta, Lis, Rosina T., Parmigiani, Giovanni, Rimm, Eric B., Finn, Stephen P., Giovannucci, Edward L., Fiorentino, Michelangelo, and Mucci, Lorelei A.
- Subjects
- *
PROSTATE cancer , *PHYSICAL activity , *PROPORTIONAL hazards models , *LONGITUDINAL method , *GENE fusion - Abstract
Growing evidence shows that clinical and molecular subtypes of prostate cancer (PCa) have specific risk factors. Observational studies suggest that physical activity may lower the risk of aggressive PCa. To our knowledge, the association between physical activity and PCa defined by TMPRSS2:ERG has not been evaluated. To prospectively examine the association between physical activity and risk of PCa defined by clinical features and TMPRSS2:ERG. We studied 49 160 men aged 40–75 yr in the Health Professionals Follow-up Study from 1986 to 2012. Data was collected at baseline and every 2 yr with >90% follow-up. Total and vigorous physical activity were measured in metabolic equivalent of task (MET)-h/wk. Advanced PCa was defined as stage T3b, T4, N1, or M1 at diagnosis and lethal PCa as distant metastases or death due to disease over follow-up. Presence of TMPRSS2:ERG was estimated by immunohistochemistry of ERG protein expression. Cox proportional hazards models were used to obtain multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) for incidence of subtype-specific PCa. During 26 yr of follow-up, 6411 developed PCa overall and 888 developed lethal disease. There were no significant associations between total physical activity and risk of PCa in the overall cohort. In multivariable-adjusted models, men in the highest quintile of vigorous activity had a significant 30% lower risk of advanced PCa (HR: 0.70, 95% CI: 0.53–0.92) and 25% lower risk of lethal PCa (HR: 0.75, 95% CI: 0.59–0.94) than men in the lowest quintile of vigorous activity. The association was independent of screening history. Vigorous activity was not associated with total PCa in the overall cohort but was inversely associated among highly screened men (top vs bottom quintile, HR: 0.83, 95% CI: 0.70–0.97). Of all cases, 945 were assayed for ERG (48% ERG-positive). Men with higher vigorous activity had a lower risk of ERG-positive PCa (top vs bottom quintile, HR: 0.71, 95% CI: 0.52–0.97). There was no significant association with the risk of ERG-negative disease (p heterogeneity = 0.09). Our study confirms that vigorous physical activity is associated with lower risk of advanced and lethal PCa and provides novel evidence for a lower risk of TMPRSS2:ERG -positive disease. The identification of modifiable lifestyle factors for prevention of clinically important prostate cancer (PCa) is needed. In this report, we compared risk of PCa in men with different levels of physical activity. Men with higher vigorous activity had a lower risk of developing advanced and lethal PCa and PCa with the common TMPRSS2:ERG gene fusion. In this prospective study of physical activity and prostate cancer among 49 160 men, vigorous activity was associated with lower risk of lethal and TMPRSS2:ERG -positive disease. Long-term vigorous activity may be beneficial in prevention of lethal prostate cancer and may involve pathways specific to TMPRSS2:ERG -positive disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Association between Trichomonas vaginalis and prostate cancer mortality.
- Author
-
Tsang, Sabrina H., Peisch, Samuel F., Rowan, Brendan, Markt, Sarah C., Gonzalez‐Feliciano, Amparo G., Sutcliffe, Siobhan, Platz, Elizabeth A., Mucci, Lorelei A., and Ebot, Ericka M.
- Abstract
We previously observed a positive association between seropositivity for the parasite Trichomonas vaginalis and risk of clinically significant prostate cancer at diagnosis. Here, we examined whether T. vaginalis seropositivity was associated with increased prostate cancer‐specific or all‐cause mortality among prostate cancer patients. We studied 736 men with prostate cancer from the Physicians' Health Study (PHS) and 749 men with prostate cancer from the Health Professionals Follow‐Up Study (HPFS). We used Cox proportional hazards regression models to estimate multivariable‐adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of the association between T. vaginalis serostatus and progression to death from prostate cancer and from all causes. In PHS, 423 men died of any cause during a median follow‐up of 13.8 years from the date of cancer diagnosis, among whom 131 died of prostate cancer. In HPFS, there were 287 deaths, including 77 deaths from prostate cancer, during a median follow‐up of 12.8 years. We found no association between T. vaginalis serostatus and either prostate cancer mortality or all‐cause mortality in either the PHS or HPFS. While previous studies suggest a possible role for T. vaginalis in the development of clinically significant prostate cancer, our findings do not support the hypothesis that T. vaginalis serostatus is associated with mortality among prostate cancer patients. What's new? The parasite Trichomonas vaginalis, a cause of sexually transmitted infection, is capable of passing through the male urethra to the prostate, where it elicits an inflammatory response. Whether that response plays a role in the development and progression of prostate cancer, however, is unclear. In our study, based on investigation of data from two separate cohorts of American male prostate cancer patients, no association was found between T. vaginalis infection and prostate cancer‐specific or all‐cause mortality. The findings suggest that T. vaginalis seropositivity does not raise mortality risk in men with prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.
- Author
-
Ahearn, Thomas U, Peisch, Sam, Pettersson, Andreas, Ebot, Ericka M, Zhou, Cindy Ke, Graff, Rebecca E, Sinnott, Jennifer A, Fazli, Ladan, Judson, Gregory L, Bismar, Tarek A, Rider, Jennifer R, Gerke, Travis, Chan, June M, Fiorentino, Michelangelo, Flavin, Richard, Sesso, Howard D, Finn, Stephen, Giovannucci, Edward L, Gleave, Martin, and Loda, Massimo
- Subjects
PROSTATE cancer ,INSULIN receptors ,PROSTATE ,CANCER invasiveness - Abstract
Circulating insulin-like growth factor-1 (IGF-1) is consistently associated with prostate cancer risk. IGF-1 binds to IGF-1 receptor (IGF1R) and insulin receptor (IR), activating cancer hallmark pathways. Experimental evidence suggests that TMPRSS2:ERG may interact with IGF/insulin signaling to influence progression. We investigated IGF1R and IR expression and its association with lethal prostate cancer among 769 men. Protein expression of IGF1R, IR and ERG (i.e. a surrogate of ERG fusion genes) were assayed by immunohistochemistry. Cox models estimated hazard ratios (HR) and 95% confidence intervals (CI) adjusted for clinical characteristics. Among patients, 29% had strong tumor IGF1R expression and 10% had strong IR expression. During a mean follow-up of 13.2 years through 2012, 80 men (11%) developed lethal disease. Tumors with strong IGF1R or IR expression showed increased cell proliferation, decreased apoptosis and a higher prevalence of ERG. In multivariable models, strong IGF1R was associated with a borderline increased risk of lethal prostate cancer (HR 1.7; 95% CI 0.9–3.1). The association appeared greater in ERG-positive tumors (HR 2.8; 95% CI 0.9–8.4) than in ERG-negative tumors (HR 1.3; 95% CI 0.6–3.0, p-heterogeneity 0.08). There was no association between IR and lethal prostate cancer (HR 0.8; 95% CI 0.4–1.9). These results suggest that tumor IGF1R expression may play a role in prostate cancer progression to a lethal phenotype and that ERG-positive tumors may be more sensitive to IGF signaling. These data may improve our understanding of IGF signaling in prostate cancer and suggest therapeutic options for disease subtypes. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer.
- Author
-
Graff, Rebecca E., Ahearn, Thomas U., Pettersson, Andreas, Ebot, Ericka M., Gerke, Travis, Penney, Kathryn L., Wilson, Kathryn M., Markt, Sarah C., Pernar, Claire H., Gonzalez-Feliciano, Amparo G., Song, Mingyang, Lis, Rosina T., Schmidt, Daniel R., Heiden, Matthew G. Vander, Fiorentino, Michelangelo, Giovannucci, Edward L., Loda, Massimo, and Mucci, Lorelei A.
- Abstract
Background: The largest molecular subtype of primary prostate cancer is defined by the TMPRSS2:ERG gene fusion. Few studies, however, have investigated etiologic differences by TMPRSS2:ERG status. Because the fusion is hormone-regulated and a man's hormonal milieu varies by height and obesity status, we hypothesized that both may be differentially associated with risk of TMPRSS2:ERG-defined disease. Methods: Our study included 49,372 men from the prospective Health Professionals Follow-up Study. Participants reported height and weight at baseline in 1986 and updated weight biennially thereafter through 2009. Tumor ERG protein expression (a TMPRSS2:ERG marker) was immunohistochemically assessed. We used multivariable competing risks models to calculate HRs and 95% confidence intervals (CIs) for the risk of ERG-positive and ERG-negative prostate cancer. Results: During 23 years of follow-up, we identified 5,847 incident prostate cancers, among which 913 were ERG-assayed. Taller height was associated with an increased risk of ERG-positive disease only [per 5 inches HR 1.24; 95% confidence interval (CI), 1.03-1.50; P
heterogeneity = 0.07]. Higher body mass index (BMI) at baseline (per 5 kg/m² HR 0.75; 95% CI, 0.61-0.91; Pheterogeneity = 0.02) and updated BMI over time (per 5 kg/m² HR 0.86; 95% CI, 0.74-1.00; Pheterogeneity = 0.07) were associated with a reduced risk of ERG-positive disease only. Conclusions: Our results indicate that anthropometrics may be uniquely associated with TMPRSS2:ERG-positive prostate cancer; taller height may be associated with greater risk, whereas obesity may be associated with lower risk. Impact: Our study provides strong rationale for further investigations of other prostate cancer risk factors that may be distinctly associated with subtypes. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
18. The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study.
- Author
-
Kelly, Rachel S., Sinnott, Jennifer A., Rider, Jennifer R., Ebot, Ericka M., Gerke, Travis, Bowden, Michaela, Pettersson, Andreas, Loda., Massimo, Sesso, Howard D., Kantoff, Philip W., Martin, Neil E., Giovannucci, Edward L., Tyekucheva, Svitlana, Heiden, Matthew Vander, and Mucci, Lorelei A.
- Published
- 2016
- Full Text
- View/download PDF
19. Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes.
- Author
-
Shui, Irene M., Wong, Chao‐Jen, Zhao, Shanshan, Kolb, Suzanne, Ebot, Ericka M., Geybels, Milan S., Rubicz, Rohina, Wright, Jonathan L., Lin, Daniel W., Klotzle, Brandy, Bibikova, Marina, Fan, Jian‐Bing, Ostrander, Elaine A., Feng, Ziding, Stanford, Janet L., Wong, Chao-Jen, and Fan, Jian-Bing
- Subjects
PROSTATE cancer ,DNA methylation ,SMOKING ,ALKYLATION ,METHYLATION ,CANCER relapse ,DNA ,GENES ,MORTALITY ,HEALTH outcome assessment ,PROGNOSIS ,PROSTATE tumors ,PROSTATECTOMY ,RESEARCH funding ,GENE expression profiling ,ODDS ratio ,TUMOR grading - Abstract
Background: DNA methylation has been hypothesized as a mechanism for explaining the association between smoking and adverse prostate cancer (PCa) outcomes. This study was aimed at assessing whether smoking is associated with prostate tumor DNA methylation and whether these alterations may explain in part the association of smoking with PCa recurrence and mortality.Methods: A total of 523 men had radical prostatectomy as their primary treatment, detailed smoking history data, long-term follow-up for PCa outcomes, and tumor tissue profiled for DNA methylation. Ninety percent of the men also had matched tumor gene expression data. A methylome-wide analysis was conducted to identify differentially methylated regions (DMRs) by smoking status. To select potential functionally relevant DMRs, their correlation with the messenger RNA (mRNA) expression of corresponding genes was evaluated. Finally, a smoking-related methylation score based on the top-ranked DMRs was created to assess its association with PCa outcomes.Results: Forty DMRs were associated with smoking status, and 10 of these were strongly correlated with mRNA expression (aldehyde oxidase 1 [AOX1], claudin 5 [CLDN5], early B-cell factor 1 [EBF1], homeobox A7 [HOXA7], lectin galactoside-binding soluble 3 [LGALS3], microtubule-associated protein τ [MAPT], protocadherin γ A [PCDHGA]/protocadherin γ B [PCDHGB], paraoxonase 3 [PON3], synaptonemal complex protein 2 like [SYCP2L], and zinc finger and SCAN domain containing 12 [ZSCAN12]). Men who were in the highest tertile for the smoking-methylation score derived from these DMRs had a higher risk of recurrence (odds ratio [OR], 2.29; 95% confidence interval [CI], 1.42-3.72) and lethal disease (OR, 4.21; 95% CI, 1.65-11.78) in comparison with men in the lower 2 tertiles.Conclusions: This integrative molecular epidemiology study supports the hypothesis that smoking-associated tumor DNA methylation changes may explain at least part of the association between smoking and adverse PCa outcomes. Future studies are warranted to confirm these findings and understand the implications for improving patient outcomes. Cancer 2016;122:2168-77. © 2016 American Cancer Society. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
20. A Metabolomics Analysis of Adiposity and Advanced Prostate Cancer Risk in the Health Professionals Follow-Up Study.
- Author
-
Dickerman, Barbra A., Ebot, Ericka M., Healy, Brian C., Wilson, Kathryn M., Eliassen, A. Heather, Ascherio, Alberto, Pernar, Claire H., Zeleznik, Oana A., Vander Heiden, Matthew G., Clish, Clary B., Giovannucci, Edward, and Mucci, Lorelei A.
- Subjects
MEDICAL personnel ,PROSTATE cancer ,METABOLOMICS ,WAIST circumference ,BODY mass index ,OBESITY - Abstract
Obesity is associated with a higher risk of advanced prostate cancer, but men with the same body mass index (BMI) may differ in their underlying metabolic health. Using metabolomics data from nested case-control studies in the Health Professionals Follow-Up Study, we calculated Pearson correlations between 165 circulating metabolites and three adiposity measures (BMI, waist circumference, and derived fat mass from a validated prediction equation) to identify adiposity-associated metabolites. We used Lasso to further select metabolites for prediction models of adiposity measures, which we used to calculate metabolic scores representing metabolic obesity. In an independent set of 212 advanced prostate cancer cases (T3b/T4/N1/M1 or lethal during follow-up) and 212 controls, we used logistic regression to evaluate the associations between adiposity measures and metabolic scores with risk of advanced disease. All adiposity measures were associated with higher blood levels of carnitines (Pearson r range, 0.16 to 0.18) and lower levels of glutamine (r = −0.19) and glycine (r, −0.29 to −0.20), in addition to alterations in various lipids. No adiposity measure or metabolic score was associated with risk of advanced prostate cancer (e.g., odds ratio for a 5 kg/m
2 increase in BMI 0.96 (95% CI: 0.73, 1.27) and BMI metabolic score 1.18 (95% CI: 0.57, 2.48)). BMI, waist circumference, and derived fat mass were associated with a broad range of metabolic alterations. Neither adiposity nor metabolic scores were associated with risk of advanced prostate cancer. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
21. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program.
- Author
-
Labbé, David P., Zadra, Giorgia, Yang, Meng, Reyes, Jaime M., Lin, Charles Y., Cacciatore, Stefano, Ebot, Ericka M., Creech, Amanda L., Giunchi, Francesca, Fiorentino, Michelangelo, Elfandy, Habiba, Syamala, Sudeepa, Karoly, Edward D., Alshalalfa, Mohammed, Erho, Nicholas, Ross, Ashley, Schaeffer, Edward M., Gibb, Ewan A., Takhar, Mandeep, and Den, Robert B.
- Subjects
HIGH-fat diet ,CANCER invasiveness ,PROSTATE cancer ,FAT content of food ,MYC oncogenes ,LOW-fat diet - Abstract
Systemic metabolic alterations associated with increased consumption of saturated fat and obesity are linked with increased risk of prostate cancer progression and mortality, but the molecular underpinnings of this association are poorly understood. Here, we demonstrate in a murine prostate cancer model, that high-fat diet (HFD) enhances the MYC transcriptional program through metabolic alterations that favour histone H4K20 hypomethylation at the promoter regions of MYC regulated genes, leading to increased cellular proliferation and tumour burden. Saturated fat intake (SFI) is also associated with an enhanced MYC transcriptional signature in prostate cancer patients. The SFI-induced MYC signature independently predicts prostate cancer progression and death. Finally, switching from a high-fat to a low-fat diet, attenuates the MYC transcriptional program in mice. Our findings suggest that in primary prostate cancer, dietary SFI contributes to tumour progression by mimicking MYC over expression, setting the stage for therapeutic approaches involving changes to the diet. Prostate cancer progression may be enhanced by a high-fat diet. Here the authors show that a diet high in saturated fats enhance the MYC-driven transcriptional program, a feature that independently predicts prostate cancer progression and death. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. Differential Gene Expression in Prostate Tissue According to Ejaculation Frequency.
- Author
-
Sinnott, Jennifer A., Brumberg, Katherine, Wilson, Kathryn M., Ebot, Ericka M., Giovannucci, Edward L., Mucci, Lorelei A., and Rider, Jennifer R.
- Subjects
- *
GENE expression profiling , *PROSTATE cancer & genetics , *EJACULATION , *SEXUAL intercourse , *TRANSCRIPTOMES , *PHYSIOLOGY - Abstract
Abstract In a prospective study of 31 925 men with 18 yr of follow-up, higher ejaculation frequency (EF) throughout adulthood was associated with lower rates of prostate cancer. To further explore this association, we evaluated whole transcriptome gene expression in the prostate tissue from study participants who developed prostate cancer between 1992 and 2004 (n = 157 tumor tissue, n = 85 adjacent normal). We tested for trends in gene expression according to the level of EF as self-reported in 1992 for ages 20–29 yr, 40–49 yr, and the year prior to the questionnaire, 1991. There were no associations between EF and gene expression in areas of tumor after accounting for multiple testing. In contrast, in the adjacent normal tissue, 409 genes and six pathways were differentially expressed at a false discovery rate ≤0.2 across categories of EF in 1991. These results suggest that ejaculation affects the expression of genes in the normal prostate tissue. The identified genes and pathways provide potential biological links between EF and prostate tumorigenesis. Patient summary To explore previous findings that men who ejaculate more frequently have lower risk of prostate cancer, we evaluated molecular alterations in the prostate tissue according to each man's frequency of ejaculation prior to diagnosis. We identified biological processes that could link ejaculation frequency and prostate cancer. Take Home Message Previous studies have found that men who ejaculate more frequently are at a lower risk of prostate cancer. We identify genes and biologic pathways that vary in the normal prostate tissue by ejaculation frequency and may link ejaculation and prostate tumor development. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
23. Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer
- Author
-
Stephen P. Finn, Svitlana Tyekucheva, Eric B. Rimm, Edward Giovannucci, Massimo Loda, Lorelei A. Mucci, Claire H. Pernar, Ericka M. Ebot, Michelangelo Fiorentino, Giovanni Parmigiani, Matthew G. Vander Heiden, Pernar, Claire H, Parmigiani, Giovanni, Giovannucci, Edward L, Rimm, Eric B, Tyekucheva, Svitlana, Loda, Massimo, Finn, Stephen P, Vander Heiden, Matthew G, Fiorentino, Michelangelo, Ebot, Ericka M, and Mucci, Lorelei A
- Subjects
0301 basic medicine ,Oncology ,Adult ,Male ,medicine.medical_specialty ,Epidemiology ,Article ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Prostate ,Internal medicine ,Gene expression ,medicine ,Humans ,Prospective Studies ,KEGG ,Gene ,Exercise ,Aged ,Tumor microenvironment ,business.industry ,Gene Expression Profiling ,Prostatic Neoplasms ,Prostate cancer, epidemiology, physical activity ,Middle Aged ,medicine.disease ,United States ,Gene expression profiling ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,business - Abstract
Background: Men engaged in high physical activity have lower risks of advanced and fatal prostate cancer. Mechanisms underlying this association are not well understood but may include systemic and tumor-specific effects. We investigated potential mechanisms linking physical activity and gene expression in prostate tissue from men with prostate cancer. Methods: We included a subset of 118 men in the Health Professionals Follow-up Study diagnosed with prostate cancer between 1986 and 2005 with whole-transcriptome gene expression profiling on tumor and adjacent normal prostate tissue and physical activity data. Long-term vigorous physical activity was self-reported as the average time spent engaged in various forms of recreational physical activity at baseline and biennially until prostate cancer diagnosis. Gene set enrichment analysis was performed among KEGG and Hallmark gene sets to identify pathways with differential expression based on vigorous physical activity. Results: In adjacent normal tissue, we identified 25 KEGG gene sets enriched (downregulated) in the highest compared with lowest quintile of vigorous physical activity at an FDR Conclusions: These findings suggest that physical activity may influence the tumor microenvironment. Future studies are needed to confirm these findings and further investigate potential mechanisms linking physical activity to lethal prostate cancer. Impact: Identification of gene expression alterations in the prostate associated with physical activity can improve our understanding of prostate cancer etiology.
- Published
- 2021
24. A prospective study of intraprostatic inflammation, focal atrophy, and progression to lethal prostate cancer
- Author
-
Massimo Loda, Tamara L. Lotan, Michelangelo Fiorentino, Francesca Giunchi, Lorelei A. Mucci, Emily M. Rencsok, Katja Fall, Angelo M. De Marzo, Elizabeth A. Platz, Ericka M. Ebot, Cindy Ke Zhou, Yiwen Zhang, Zhang, Yiwen, Zhou, Cindy Ke, Rencsok, Emily M, Fall, Katja, Lotan, Tamara L, Loda, Massimo, Giunchi, Francesca, Platz, Elizabeth A, De Marzo, Angelo M, Mucci, Lorelei A, Fiorentino, Michelangelo, and Ebot, Ericka M
- Subjects
0301 basic medicine ,Oncology ,Adult ,Male ,medicine.medical_specialty ,Epidemiology ,H&E stain ,Inflammation ,Disease ,Article ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Aged ,Aged, 80 and over ,Genitourinary system ,Proportional hazards model ,business.industry ,Confounding ,Inflammation, focal atrophy, prostate cancer ,Prostatic Neoplasms ,Middle Aged ,medicine.disease ,Prognosis ,Prostatitis ,030104 developmental biology ,030220 oncology & carcinogenesis ,Disease Progression ,medicine.symptom ,Atrophy ,business ,Follow-Up Studies - Abstract
Background: Inflammation and focal atrophy are common features adjacent to prostate tumors. Limited evidence exists on whether these features have prognostic significance. Methods: In the Health Professionals Follow-Up Study and Physicians' Health Study, we studied 1,035 men diagnosed with prostate cancer. A genitourinary pathologist centrally reviewed tumor and normal areas of hematoxylin and eosin slides from prostate cancer specimens for the presence of acute and chronic inflammation, and four subtypes of focal atrophy. Cox proportional hazards models adjusted for potential confounders were used to estimate HRs and 95% confidence intervals (CI) for the association of these features with lethal prostate cancer, defined as development of metastatic disease or death during follow-up. Results: During a median of 12 years of follow-up, 153 men developed lethal prostate cancer. A total of 84% of men had histologic evidence of chronic inflammation and 30% had acute inflammation. Both chronic and acute inflammation were inversely associated with lethal prostate cancer in age- and lifestyle-adjusted models. Chronic inflammation remained inversely associated with lethal prostate cancer after additionally adjusting for prognostic clinical features (HR = 0.45; 95% CI, 0.30–0.69 for mild and HR = 0.51; 95% CI, 0.33–0.80 for moderate to severe). None of the atrophic lesions were associated with lethal prostate cancer. Conclusions: Our data suggest that the presence of inflammation, particularly chronic inflammation, in prostate cancer tissue is associated with better prognosis among patients with prostate cancer. Impact: This is the largest prospective cohort study to examine the association between inflammation, focal atrophy, and lethal prostate cancer.
- Published
- 2019
25. Height, obesity, and the risk of TMPRSS2: ERG-Defined prostate cancer
- Author
-
Andreas Pettersson, Claire H. Pernar, Rosina T. Lis, Massimo Loda, Daniel R. Schmidt, Michelangelo Fiorentino, Mingyang Song, Edward Giovannucci, Sarah C. Markt, Travis Gerke, Ericka M. Ebot, Kathryn L. Penney, Rebecca E. Graff, Kathryn M. Wilson, Matthew G. Vander Heiden, Lorelei A. Mucci, Thomas U. Ahearn, Amparo G. Gonzalez-Feliciano, Graff, Rebecca E., Ahearn, Thomas U., Pettersson, Andrea, Ebot, Ericka M., Gerke, Travi, Penney, Kathryn L., Wilson, Kathryn M., Markt, Sarah C., Pernar, Claire H., Gonzalez-Feliciano, Amparo G., Song, Mingyang, Lis, Rosina T., Schmidt, Daniel R., Vander Heiden, Matthew G., Fiorentino, Michelangelo, Giovannucci, Edward L., Loda, Massimo, and Mucci, Lorelei A.
- Subjects
0301 basic medicine ,Oncology ,Gynecology ,medicine.medical_specialty ,business.industry ,Epidemiology ,Cancer ,medicine.disease ,TMPRSS2 ,Confidence interval ,03 medical and health sciences ,Prostate cancer ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Prostate ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Prospective cohort study ,business ,Erg ,Body mass index - Abstract
Background: The largest molecular subtype of primary prostate cancer is defined by the TMPRSS2:ERG gene fusion. Few studies, however, have investigated etiologic differences by TMPRSS2:ERG status. Because the fusion is hormone-regulated and a man's hormonal milieu varies by height and obesity status, we hypothesized that both may be differentially associated with risk of TMPRSS2:ERG-defined disease. Methods: Our study included 49,372 men from the prospective Health Professionals Follow-up Study. Participants reported height and weight at baseline in 1986 and updated weight biennially thereafter through 2009. Tumor ERG protein expression (a TMPRSS2:ERG marker) was immunohistochemically assessed. We used multivariable competing risks models to calculate HRs and 95% confidence intervals (CIs) for the risk of ERG-positive and ERG-negative prostate cancer. Results: During 23 years of follow-up, we identified 5,847 incident prostate cancers, among which 913 were ERG-assayed. Taller height was associated with an increased risk of ERG-positive disease only [per 5 inches HR 1.24; 95% confidence interval (CI), 1.03–1.50; Pheterogeneity = 0.07]. Higher body mass index (BMI) at baseline (per 5 kg/m2 HR 0.75; 95% CI, 0.61–0.91; Pheterogeneity = 0.02) and updated BMI over time (per 5 kg/m2 HR 0.86; 95% CI, 0.74–1.00; Pheterogeneity = 0.07) were associated with a reduced risk of ERG-positive disease only. Conclusions: Our results indicate that anthropometrics may be uniquely associated with TMPRSS2:ERG-positive prostate cancer; taller height may be associated with greater risk, whereas obesity may be associated with lower risk. Impact: Our study provides strong rationale for further investigations of other prostate cancer risk factors that may be distinctly associated with subtypes. Cancer Epidemiol Biomarkers Prev; 27(2); 193–200. ©2017 AACR.
- Published
- 2018
26. Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
- Author
-
He J, Kalinava N, Doshi P, Pavlick DC, Albacker LA, Ebot EM, Tukachinsky H, Pratt J, Fusaro G, Oxnard GR, Green G, Fabrizio D, and Baden J
- Subjects
- Humans, Nivolumab therapeutic use, Ipilimumab therapeutic use, Genomics, Biomarkers, Tumor genetics, Antineoplastic Agents, Immunological therapeutic use, Neoplasms drug therapy, Neoplasms genetics, Neoplasms, Second Primary drug therapy
- Abstract
Background: An accumulation of somatic mutations in tumors leads to increased neoantigen levels and antitumor immune response. Tumor mutational burden (TMB) reflects the rate of somatic mutations in the tumor genome, as determined from tumor tissue (tTMB) or blood (bTMB). While high tTMB is a biomarker of immune checkpoint inhibitor (ICI) treatment efficacy, few studies have explored the clinical utility of bTMB, a less invasive alternative for TMB assessment. Establishing the correlation between tTMB and bTMB would provide insight into whether bTMB is a potential substitute for tTMB. We explored the tumor genomes of patients enrolled in CheckMate 848 with measurable TMB. The correlation between tTMB and bTMB, and the factors affecting it, were evaluated., Methods: In the phase 2 CheckMate 848 (NCT03668119) study, immuno-oncology-naïve patients with advanced, metastatic, or unresectable solid tumors and tTMB-high or bTMB-high (≥10 mut/Mb) were prospectively randomized 2:1 to receive nivolumab plus ipilimumab or nivolumab monotherapy. Tissue and plasma DNA sequencing was performed using the Foundation Medicine FoundationOne CDx and bTMB Clinical Trial Assays, respectively. tTMB was quantified from coding variants, insertions, and deletions, and bTMB from somatic base substitutions. Correlations between tTMB and bTMB were determined across samples and with respect to maximum somatic allele frequency (MSAF). Assay agreement and variant composition were also evaluated., Results: A total of 1,438 and 1,720 unique tissue and blood samples, respectively, were obtained from 1,954 patients and included >100 screened disease ontologies, with 1,017 unique pairs of tTMB and bTMB measurements available for assessment. Median tTMB and bTMB were 3.8 and 3.5 mut/Mb, respectively. A significant correlation between tTMB and bTMB (r=0.48, p<0.0001) was observed across all sample pairs, which increased to r=0.54 (p<0.0001) for samples with MSAF≥1%. Assay concordance was highest for samples with MSAF≥10% across multiple disease ontologies and observed for both responders and non-responders to ICI therapy. The variants contributing to tTMB and bTMB were similar., Conclusions: We observed that tTMB and bTMB had a statistically significant correlation, particularly for samples with high MSAF, and that this correlation applied across disease ontologies. Further investigation into the clinical utility of bTMB is warranted., Competing Interests: Competing interests: DF, DCP, EME, GRO, HT, JH, and LAA are employees of Foundation Medicine, Inc. and hold stock in Bristol Myers Squibb. GF, GG, and JP are employees of and hold stock in Bristol Myers Squibb. JB is an employee of and holds stock in Bristol Myers Squibb, and holds stock in Johnson and Johnson. NK holds stock in Bristol Myers Squibb. PD is a former employee of Bristol Myers Squibb., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
27. Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation.
- Author
-
Sivakumar S, Moore JA, Montesion M, Sharaf R, Lin DI, Colón CI, Fleishmann Z, Ebot EM, Newberg JY, Mills JM, Hegde PS, Pan Q, Dowlati A, Frampton GM, Sage J, and Lovly CM
- Subjects
- Humans, Mutation, Small Cell Lung Carcinoma pathology, Lung Neoplasms pathology, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Neuroendocrine genetics
- Abstract
Small cell lung cancer (SCLC) is a recalcitrant neuroendocrine carcinoma with dismal survival outcomes. A major barrier in the field has been the relative paucity of human tumors studied. Here we provide an integrated analysis of 3,600 "real-world" SCLC cases. This large cohort allowed us to identify new recurrent alterations and genetic subtypes, including STK11-mutant tumors (1.7%) and TP53/RB1 wild-type tumors (5.5%), as well as rare cases that were human papillomavirus-positive. In our cohort, gene amplifications on 4q12 are associated with increased overall survival, whereas CCNE1 amplification is associated with decreased overall survival. We also identify more frequent alterations in the PTEN pathway in brain metastases. Finally, profiling cases of SCLC containing oncogenic drivers typically associated with NSCLC demonstrates that SCLC transformation may occur across multiple distinct molecular cohorts of NSCLC. These novel and unsuspected genetic features of SCLC may help personalize treatment approaches for this fatal form of cancer., Significance: Minimal changes in therapy and survival outcomes have occurred in SCLC for the past four decades. The identification of new genetic subtypes and novel recurrent mutations as well as an improved understanding of the mechanisms of transformation to SCLC from NSCLC may guide the development of personalized therapies for subsets of patients with SCLC. This article is highlighted in the In This Issue feature, p. 1501., (©2023 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
28. Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.
- Author
-
Stopsack KH, Su XA, Vaselkiv JB, Graff RE, Ebot EM, Pettersson A, Lis RT, Fiorentino M, Loda M, Penney KL, Lotan TL, and Mucci LA
- Subjects
- Male, Humans, Oncogene Proteins, Fusion genetics, Proto-Oncogene Proteins c-ets genetics, Gene Expression Profiling, Transcriptional Regulator ERG genetics, Serine Endopeptidases genetics, Transcriptome, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology
- Abstract
The most common somatic event in primary prostate cancer is a fusion between the androgen-related TMPRSS2 gene and the ERG oncogene. Tumors with these fusions, which occur early in carcinogenesis, have a distinctive etiology. A smaller subset of other tumors harbor fusions between TMPRSS2 and members of the ETS transcription factor family other than ERG. To assess the genomic similarity of tumors with non-ERG ETS fusions and those with fusions involving ERG, this study derived a transcriptomic signature of non-ERG ETS fusions and assessed this signature and ERG-related gene expression in 1,050 men with primary prostate cancer from three independent population-based and hospital-based studies. Although non-ERG ETS fusions involving ETV1, ETV4, ETV5, or FLI1 were individually rare, they jointly accounted for one in seven prostate tumors. Genes differentially regulated between non-ERG ETS tumors and tumors without ETS fusions showed similar differential expression when ERG tumors and tumors without ETS fusions were compared (differences explained: R2 = 69-77%), including ETS-related androgen receptor (AR) target genes. Differences appeared to result from similarities among ETS tumors rather than similarities among non-ETS tumors. Gene sets associated with ERG fusions were consistent with gene sets associated with non-ERG ETS fusions, including fatty acid and amino acid metabolism, an observation that was robust across cohorts., Implications: Considering ETS fusions jointly may be useful for etiologic studies on prostate cancer, given that the transcriptome is profoundly impacted by ERG and non-ERG ETS fusions in a largely similar fashion, most notably genes regulating metabolic pathways., (©2022 American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
29. Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes.
- Author
-
Feng X, Zhou CK, Clish CB, Wilson KM, Pernar CH, Dickerman BA, Loda M, Finn SP, Penney KL, Schmidt DR, Vander Heiden MG, Giovannucci EL, Ebot EM, and Mucci LA
- Subjects
- Biomarkers, Tumor, Case-Control Studies, Follow-Up Studies, Humans, Male, Metabolomics, Prospective Studies, Prostatic Neoplasms epidemiology, Transcriptional Regulator ERG genetics, PTEN Phosphohydrolase genetics, Prostatic Neoplasms genetics
- Abstract
Background: The TMPRSS2:ERG gene fusion and PTEN loss are two of the most common somatic molecular alterations in prostate cancer. Here, we investigated the association of prediagnostic-circulating metabolomics and prostate cancer defined by ERG or PTEN status to improve understanding of these etiologically distinct molecular prostate cancer subtypes., Methods: The study was performed among 277 prostate cancer cases with ERG status, 211 with PTEN status, and 294 controls nested in the Health Professionals Follow-up Study (HPFS) and the Physicians' Health Study (PHS). We profiled 223 polar and non-polar metabolites using LC-MS in prediagnostic plasma specimens. We applied enrichment analysis and multinomial logistic regression models to identify biological metabolite classes and individual metabolites associated with prostate cancer defined by ERG or PTEN status., Results: Compared with noncancer controls, sphingomyelin ( P : 0.01), ceramide ( P : 0.04), and phosphatidylethanolamine ( P : 0.03) circulating levels were enriched among ERG-positive prostate cancer cases. Sphingomyelins ( P : 0.02), ceramides ( P : 0.005), and amino acids ( P : 0.02) were enriched among tumors exhibiting PTEN-loss; unsaturated diacylglycerols ( P : 0.003) were enriched among PTEN-intact cases; and unsaturated triacylglycerols were enriched among both PTEN-loss ( P : 0.001) and PTEN-intact ( P : 0.0001) cases. Although several individual metabolites identified in the above categories were nominally associated with ERG or PTEN-defined prostate cancer, none remained significant after accounting for multiple testing., Conclusions: The molecular process of prostate carcinogenesis may be distinct for men with different metabolomic profiles., Impact: These novel findings provide insights into the metabolic environment for the development of prostate cancer., (©2021 American Association for Cancer Research.)
- Published
- 2021
- Full Text
- View/download PDF
30. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer.
- Author
-
Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Ahearn TU, Gerke TA, Downer MK, Rider JR, Freedland SJ, Lotan TL, Kantoff PW, Platz EA, Loda M, Stampfer MJ, Giovannucci E, Sweeney CJ, Finn SP, and Mucci LA
- Subjects
- Adult, Aged, Biomarkers, Tumor metabolism, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Neoplasm Metastasis, PTEN Phosphohydrolase metabolism, Prospective Studies, Prostatic Neoplasms epidemiology, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology, Risk Assessment, Risk Factors, Survival Rate, Transcriptional Regulator ERG genetics, Transcriptional Regulator ERG metabolism, United States epidemiology, Biomarkers, Tumor genetics, Gene Expression Regulation, Neoplastic drug effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, PTEN Phosphohydrolase genetics, Prostatic Neoplasms drug therapy
- Abstract
Purpose: Statins are associated with lower risk of aggressive prostate cancer, but lethal prostate cancer is understudied and contributing mechanisms are unclear. We prospectively examined statins and lethal prostate cancer risk in the Health Professionals Follow-up Study (HPFS), tested associations with molecular subtypes, and integrated gene expression profiling to identify putative mechanisms., Experimental Design: Our study included 44,126 men cancer-free in 1990, followed for prostate cancer incidence through 2014, with statin use recorded on biennial questionnaires. We used multivariable Cox regression to examine associations between statins and prostate cancer risk overall, by measures of clinically significant disease, and by ERG and PTEN status. In an exploratory analysis, age-adjusted gene set enrichment analysis identified statin-associated pathways enriched in tumor and adjacent normal prostate tissue., Results: During 24 years of follow-up, 6,305 prostate cancers were diagnosed and 801 (13%) were lethal (metastatic at diagnosis or metastatic/fatal during follow-up). Relative to never/past use, current statin use was inversely associated with risk of lethal prostate cancer [HR, 0.76; 95% confidence interval (CI), 0.60-0.96] but not overall disease. We found a strong inverse association for risk of PTEN-null cancers (HR, 0.40; 95% CI, 0.19-0.87) but not PTEN-intact cancers (HR, 1.18; 95% CI, 0.95-1.48; P heterogeneity = 0.01). Associations did not differ by ERG. Inflammation and immune pathways were enriched in normal prostate tissue of statin ever ( n = 10) versus never users ( n = 103)., Conclusions: Molecular tumor classification identified PTEN and inflammation/immune activation as potential mechanisms linking statins with lower lethal prostate cancer risk. These findings support a potential causal association and could inform selection of relevant biomarkers for statin clinical trials., (©2019 American Association for Cancer Research.)
- Published
- 2020
- Full Text
- View/download PDF
31. A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer.
- Author
-
Zhang Y, Zhou CK, Rencsok EM, Fall K, Lotan TL, Loda M, Giunchi F, Platz EA, De Marzo AM, Mucci LA, Fiorentino M, and Ebot EM
- Subjects
- Adult, Aged, Aged, 80 and over, Disease Progression, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Atrophy complications, Inflammation complications, Prostatic Neoplasms etiology, Prostatic Neoplasms pathology, Prostatitis complications
- Abstract
Background: Inflammation and focal atrophy are common features adjacent to prostate tumors. Limited evidence exists on whether these features have prognostic significance., Methods: In the Health Professionals Follow-Up Study and Physicians' Health Study, we studied 1,035 men diagnosed with prostate cancer. A genitourinary pathologist centrally reviewed tumor and normal areas of hematoxylin and eosin slides from prostate cancer specimens for the presence of acute and chronic inflammation, and four subtypes of focal atrophy. Cox proportional hazards models adjusted for potential confounders were used to estimate HRs and 95% confidence intervals (CI) for the association of these features with lethal prostate cancer, defined as development of metastatic disease or death during follow-up., Results: During a median of 12 years of follow-up, 153 men developed lethal prostate cancer. A total of 84% of men had histologic evidence of chronic inflammation and 30% had acute inflammation. Both chronic and acute inflammation were inversely associated with lethal prostate cancer in age- and lifestyle-adjusted models. Chronic inflammation remained inversely associated with lethal prostate cancer after additionally adjusting for prognostic clinical features (HR = 0.45; 95% CI, 0.30-0.69 for mild and HR = 0.51; 95% CI, 0.33-0.80 for moderate to severe). None of the atrophic lesions were associated with lethal prostate cancer., Conclusions: Our data suggest that the presence of inflammation, particularly chronic inflammation, in prostate cancer tissue is associated with better prognosis among patients with prostate cancer., Impact: This is the largest prospective cohort study to examine the association between inflammation, focal atrophy, and lethal prostate cancer., (©2019 American Association for Cancer Research.)
- Published
- 2019
- Full Text
- View/download PDF
32. The Epidemiology of Prostate Cancer.
- Author
-
Pernar CH, Ebot EM, Wilson KM, and Mucci LA
- Subjects
- Age Factors, Animals, Black People statistics & numerical data, Body Height, Coffee, Exercise, Fishes, Humans, Solanum lycopersicum, Male, Medical History Taking, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Protective Factors, Risk Factors, Vitamin D, Diet statistics & numerical data, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Obesity epidemiology, Prostatic Neoplasms epidemiology, Smoking epidemiology
- Abstract
Prostate cancer is a major cause of disease and mortality among men, and each year 1.6 million men are diagnosed with and 366,000 men die of prostate cancer. In this review, we discuss the state of evidence for specific genetic, lifestyle, and dietary factors associated with prostate cancer risk. Given the biological heterogeneity of this cancer, we focus on risk factors for advanced or fatal prostate cancer. First, we provide descriptive epidemiology statistics and patterns for prostate cancer incidence and mortality around the world. This includes discussion of the impact of prostate-specific antigen screening on prostate cancer epidemiology. Next, we summarize evidence for selected risk factors for which there is strong or probable evidence of an association: genetics, obesity and weight change, physical activity, smoking, lycopene and tomatoes, fish, vitamin D and calcium, and statins. Finally, we highlight future directions for prostate cancer epidemiology research., (Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
33. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
- Author
-
Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, and Lotan TL
- Subjects
- Age Factors, Aged, Body Mass Index, Disease Progression, Follow-Up Studies, Gene Expression Regulation, Neoplastic, Health Personnel statistics & numerical data, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Male, Neoplasm Grading, Neoplasm Staging, Odds Ratio, Physicians statistics & numerical data, Proportional Hazards Models, Prospective Studies, Prostatic Neoplasms chemistry, Prostatic Neoplasms surgery, Risk Assessment, Transcriptional Regulator ERG, United States epidemiology, Biomarkers, Tumor analysis, Oncogene Proteins, Fusion analysis, PTEN Phosphohydrolase analysis, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Serine Endopeptidases analysis, Trans-Activators analysis, Tumor Suppressor Proteins analysis
- Abstract
Background: PTEN is a tumor suppressor frequently deleted in prostate cancer that may be a useful prognostic biomarker. However, the association of PTEN loss with lethal disease has not been tested in a large, predominantly surgically treated cohort., Methods: In the Health Professionals Follow-up Study and Physicians' Health Study, we followed 1044 incident prostate cancer cases diagnosed between 1986 and 2009 for cancer-specific and all-cause mortality. A genetically validated PTEN immunohistochemistry (IHC) assay was performed on tissue microarrays (TMAs). TMPRSS2:ERG status was previously assessed in a subset of cases by a genetically validated IHC assay for ERG. Cox proportional hazards models adjusting for age and body mass index at diagnosis, Gleason grade, and clinical or pathologic TNM stage were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association with lethal disease. All statistical tests were two-sided., Results: On average, men were followed 11.7 years, during which there were 81 lethal events. Sixteen percent of cases had complete PTEN loss in all TMA cores and 9% had heterogeneous PTEN loss across cores. After adjustment for clinical-pathologic variables, complete PTEN loss was associated with lethal progression (HR = 1.8, 95% CI = 1.2 to 2.9). The association of PTEN loss (complete or heterogeneous) with lethal progression was only among men with ERG-negative (HR = 3.1, 95% CI = 1.7 to 5.7) but not ERG-positive (HR = 1.2, 95% CI = 0.7 to 2.2) tumors., Conclusions: PTEN loss is independently associated with increased risk of lethal progression, particularly in the ERG fusion-negative subgroup. These validated and inexpensive IHC assays may be useful for risk stratification in prostate cancer., (© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.